Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmri.28796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced Hybrid Closed Loop Algorithm Use in Type 1 Diabetes: The French MiniMed™ Glycemic Control and Quality of Life Study.
Diabetes Ther
December 2024
Medtronic, Tolochenaz, Switzerland.
Introduction: The MiniMed™ 780G system uses an advanced hybrid closed loop algorithm to improve outcomes in people with type 1 diabetes (T1D). The MiniMed™ 780G Glycemic Control and Quality of Life (EQOL) study aimed to provide routine clinical practice data on system effectiveness and associated patient-reported outcomes (PROs) in France.
Methods: Individuals aged ≥ 7 years with T1D were enrolled.
Rationale and strategies for improving glycaemic control in diabetic patients undergoing cardiac surgery: a narrative review.
J Thorac Dis
November 2024
Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK.
Background And Objective: The global prevalence of diabetes mellitus has markedly risen in recent years. Consequently, there has been a rise in the number of patients with diabetes undergoing cardiac surgery. Despite the existence of national and international guidelines to improve surgical outcomes in patients with diabetes, perioperative diabetes management optimisation remains inadequate resulting in these patients experiencing increased rates of surgical morbidity and mortality.
View Article and Find Full Text PDFWhat is the optimal dialysis method for diabetic patients with end stage kidney disease?
World J Diabetes
December 2024
Department of Nursing & Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar.
Diabetes is one of the most catastrophic diseases ruling every corner of the world, and this has led to elevated incidents of end-stage kidney disease (ESKD). The standard treatment for ESKD is kidney transplantation/replacement, which is limited due to a deficiency of donors. Hence, dialysis has become the second-best option for treating patients with ESKD.
View Article and Find Full Text PDFIntestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management.
World J Diabetes
December 2024
Department of Endocrinology and Metabolism, The Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and the need for exogenous insulin. A significant concern in T1D management is hypoglycemia, which is worsened by impaired counterregulatory mechanisms. Effective counterregulation involves hormones such as glucagon and adrenaline, which work to restore normal blood glucose levels.
View Article and Find Full Text PDFPromise of the gut microbiota in prevention and traditional Chinese medicine treatment of diabetic peripheral neuropathy.
World J Diabetes
December 2024
Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China.
The pathogenesis of diabetic peripheral neuropathy (DPN) has not been fully elucidated, and treatment options are limited. Currently, the main strategies for treating DPN are strict glycemic control and symptomatic pain relief. In this editorial, we comment on an article by Li which suggested that modulating the gut microbiota using traditional Chinese medicine (TCM) may be a promising strategy for alleviating DPN symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!